Kite, A Gilead Company, Announces Completion Of Marketing Authorization Transfer For Yescarta Car T-Cell Therapy In Japan
Portfolio Pulse from Happy Mohamed
Kite Pharma, a Gilead Company, has announced the completion of the Marketing Authorization transfer for Yescarta CAR T-cell therapy in Japan from Daiichi Sankyo to Gilead Sciences K.K. The Kite Cell Therapy Business Unit of Gilead Sciences K.K. will now manage the sales and promotion activities of Yescarta in Japan.
June 22, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences K.K. has completed the Marketing Authorization transfer for Yescarta CAR T-cell therapy in Japan, allowing the company to manage sales and promotion activities.
The completion of the Marketing Authorization transfer for Yescarta in Japan allows Gilead Sciences K.K. to manage the sales and promotion activities of the therapy. This could lead to increased sales and revenue for the company, as they can now fully leverage their manufacturing expertise and commercialization capabilities to meet the increasing demand for the therapy in Japan.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100